| Talaris Therapeutics is a late-clinical stage, cell therapy company developing a method of allogeneic hematopoietic stem cell transplantation (allo-HSCT) that has the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases and certain severe blood, immune and metabolic disorders. In the organ transplant setting, which it calls Facilitated Allo-HSCT Therapy, could prevent organ rejection without the morbidity. Co.'s primary product candidate, FCR001, which is central to its Facilitated Allo-HSCT Therapy, is an allogeneic cell therapy comprised of stem and immune cells that are procured from a healthy donor. The TALS average annual return since 2021 is shown above.
The Average Annual Return on the TALS average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether TALS average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the TALS average annual return calculation with any dividends reinvested as applicable (on ex-dates).